JNJ-64041757 (JNJ-757), a Live, Attenuated, Double-Deleted
JNJ-757
LADD Lm
Mesothelin
Non–small cell lung cancer
Vaccine
Journal
JTO clinical and research reports
ISSN: 2666-3643
Titre abrégé: JTO Clin Res Rep
Pays: United States
ID NLM: 101769967
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
04
08
2020
revised:
22
09
2020
accepted:
23
09
2020
entrez:
30
9
2021
pubmed:
1
10
2021
medline:
1
10
2021
Statut:
epublish
Résumé
JNJ-64041757 (JNJ-757) is a live, attenuated, double-deleted Patients with stage IIIB/IV NSCLC who had received previous therapy were treated with JNJ-757 (1 × 10 In the monotherapy study, 18 patients (median age 63.5 y; women 61%) were treated with JNJ-757 (1 × 10 As monotherapy, JNJ-757 was immunogenic and tolerable, with mild infusion-related fever and chills. The limited efficacy of JNJ-757, alone or with nivolumab, did not warrant further investigation of the combination.
Identifiants
pubmed: 34589981
doi: 10.1016/j.jtocrr.2020.100103
pii: S2666-3643(20)30149-1
pmc: PMC8474274
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100103Informations de copyright
© 2020 The Authors.
Références
Immunol Rev. 1997 Aug;158:129-36
pubmed: 9314081
Am J Surg Pathol. 2003 Feb;27(2):150-8
pubmed: 12548160
Hum Pathol. 2003 Jun;34(6):605-9
pubmed: 12827615
J Immunother. 2013 Nov-Dec;36(9):468-76
pubmed: 24145358
J Clin Oncol. 2008 Mar 20;26(9):1452-8
pubmed: 18349395
Clin Cancer Res. 2014 Jul 15;20(14):3660-71
pubmed: 24788102
J Immunol. 2013 Mar 15;190(6):2501-9
pubmed: 23396941
Am J Surg Pathol. 2003 Aug;27(8):1031-51
pubmed: 12883236
Clin Cancer Res. 2012 Feb 1;18(3):858-68
pubmed: 22147941
Mayo Clin Proc. 2008 May;83(5):584-94
pubmed: 18452692
Lancet Oncol. 2014 Jan;15(1):59-68
pubmed: 24331154
Proc Natl Acad Sci U S A. 2004 Sep 21;101(38):13832-7
pubmed: 15365184
JAMA Oncol. 2019 Oct 1;5(10):1411-1420
pubmed: 31343665
Oncotarget. 2015 May 10;6(13):11694-703
pubmed: 26028668
Eur J Cancer. 2015 Nov;51(16):2321-9
pubmed: 26283035
Crit Rev Oncol Hematol. 2012 Sep;83(3):432-43
pubmed: 22366114
J Immunother Cancer. 2013 Aug 29;1:15
pubmed: 24829751
Cancer Biol Ther. 2007 Dec;6(12):1847-52
pubmed: 18075301
Adv Cancer Res. 2013;119:421-75
pubmed: 23870514
Front Cell Infect Microbiol. 2014 May 12;4:51
pubmed: 24860789
J Thorac Dis. 2018 May;10(Suppl 13):S1602-S1614
pubmed: 29951309
Front Immunol. 2017 Mar 13;8:269
pubmed: 28348561
Cancer Immunol Immunother. 2008 Sep;57(9):1301-13
pubmed: 18273616
Lancet Oncol. 2016 Jun;17(6):822-835
pubmed: 27132212
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
Clin Cancer Res. 2016 Aug 1;22(15):3782-90
pubmed: 26927662
Mod Pathol. 2006 Mar;19(3):417-28
pubmed: 16415794
Pathol Int. 2007 Apr;57(4):190-9
pubmed: 17316414
Cancer Treat Res. 2005;123:61-88
pubmed: 16211866
J Clin Oncol. 2019 Oct 1;37(28):2518-2527
pubmed: 31154919
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Cells. 2020 Aug 25;9(9):
pubmed: 32854442
J Immunother. 2013 Oct;36(8):442-50
pubmed: 23994887
Adv Immunol. 2006;90:51-81
pubmed: 16730261